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tical expenditure per capita Δ x2009-2012= -37,6%, x2012= 282 € , rebate from pharma-
ceutical companies Δ x2009-2012= +364,1%, net public pharmaceutical expenditure 
Δ x2009-2012= -42,3%, x2012= 2.88 mil € , net public pharmaceutical expenditure per 
capita Δ x2009-2012= -43%, x2012 = 253 € , net public pharmaceutical expenditure as % 
of GDP Δ x2009-2012= -36,3% and in 2012 they constituted 1,4% GDP. Price changes of 
medicines Δ x2005-2011= -17,8%, Δ x2010-2011= -10,7%. ConClusions: Interventions 
implemented in 2010 had according presented parameters a great impact on effec-
tiveness of Health care and Pharmaceutical sector and this improvement will con-
tinue for a few years more. The betterment of Health care and Pharmaceutical sector 
might help to lower the public debt and recover economic credibility of Greece.
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objeCtives: Hopital’s attractiveness can impact the number of inpatients, and so 
health care expenditures. The objective is to identify parameters related to patients 
or drugs, wich influence the proportion of inpatients not residing in the hospital’s 
region, in order to better understand expensive drug expenditures. Methods: A 
database on expensive inpatient drugs listed on a national formulary was set up, 
with information related to drugs -from National and European Health authori-
ties- and patients -from our university hospital centre’s database (UHC) of the 
Paris region. A censored regression model, Tobit model, was developed in which 
the dependent variable was, for each drug, the ratio of the number of inpatients not 
residing in the Paris region, on the total number of inpatients receiving this drug. 
Explanatory variables were related to drugs and to patients. All statistical tests 
were run in Stata/IC13®. Results: During 2012, 526 091 doses -of the 113 drugs 
list- are administered to 30 499 UHC inpatients. 13% of inpatients come from off 
the Paris region. According to the Tobit model, three variables positively impact the 
ratio (innovative status, percentage of women and Diagnosis Related Group coded 
as severe) and three negatively (orphan designation, percentage of patients over 
65 years old, biological origin). Therapeutic classes and Major Diagnostic Categories 
also impact significantly the ratio according to the statistic class. For instance, 
innovative status, defined by a market authorization granted in the five last years 
and a high level of improvement in actual benefit, improves the ratio of 8.6 points. 
To benefit from the most innovative treatments, patients tend to be cared in UHC’s 
hospitals. ConClusions: This study represents the first step of modelling signifi-
cant determinants of hospital’s attractiveness for patients. It focuses, quite uniquely, 
on patients and drugs factors, and could be extended to other variables.
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objeCtives: Clinical researches are an important tool for the improvement of 
medicine and significant economic value. The aim of this study was to investigate 
the economic impact of clinical researches to the research centers and reimburse-
ment system in Turkey. Methods: Budget of clinical trials were calculated from 
the raw data of the Report of Istanbul Medical Faculty Clinical Researches (ITFKAR) 
between years 2006-2010. In addition, the possible cost of the drugs that were used 
in the clinical researches for SGK was calculated for showing the cost of medicines 
acquired with clinical researches. It has been accepted that predicted budgets of 
reviewed files were spent for research. Similarly, it has been accepted that the num-
ber of patients was not changed during the studies. Thus, approved budgets could 
be accepted as drug investment of the approval year. For the calculation of drug 
costs, discounted reimbursement figures of Social Security Administration (SGK) 
for licenced products were used. If not licenced and imported via Turkish Chamber 
of Pharmacists, the prices of abroad drug list of SGK were used. Calculations were 
performed with the drug prices for the year 2013. Results: The average of drug cost 
savings per patient with participation to the clinical research and clinical research 
investment per patient were calculated as US$ 21.649 and US$ 4.879. It could be said 
that total budget of sponsored pharmaceutical researches was US$107 million and 
the government had a saving close to US$ 311.096.130 due to not reimbursing the 
cost of drugs of the patients who were included to the clinical researches in Turkey 
depending on the analysis. ConClusions: However study is based on assump-
tions, the findings are unique for the literature. The health policy makers can take 
account the study of the policy improvements about clinical trials in Turkey.
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objeCtives: With population of more than 1 Billion, Africa is the world’s second 
largest continent. The transition that African countries are undergoing is a real 
challenge for health care authorities. 24% of the global disease burden is accounted 
in Africa. The diseases that prevailed in the 60s and 70s have not completely disap-
peared, tuberculosis is still endemic as well as transmissible diseases like HIV/AIDS 
and Hepatitis still remained as a major problem while some others, such as cancers, 
cardiovascular and metabolic disorders are dramatically increasing, requiring the 
implementation of effective health care programs and leading to an increasing 
demand for drugs treatment. Methods: Inventory of the potential of Africa in 
clinical research. Results: In 2012, African Pharmaceutical market revenue was 
USD 18 Billion and expected to reach USD 30 Billion by 2016. Established countries in 
both Sub-Saharan and North African countries (South Africa, Nigeria, Cote d’Ivoire, 
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objeCtives: In 2011 the budget of the public payer in Poland, National Health Fund 
(NHF) amounted to 58.2 bln PLN. 47.3% of these funds was allocated to fund hospital 
treatment which is based on diagnosis-related groups (DRGs) but also includes 
innovative, expensive drugs (i. a. chemotherapy, orphan). The aim of the paper was 
to identify the existing correlation between hospital morbidity and the average unit 
cost of hospital treatment in various chronic diseases. Comparison of individual 
hospital costs of treatment different chronic diseases with varying degrees of sever-
ity, different course and level of incidence (from common to ultrarare) open the 
possibility of presenting the correlation between morbidity and unitary medical 
costs incurred by the NHF for the treatment of various indications. Methods: 
The analysis was prepared for 23 therapeutic areas, which were divided into 4 
categories (diseases: common, infectious, pediatric and rare /ultrarare), diversified 
both in terms of severity and morbidity. This choice gave a possibility of comparing 
a wide range of chronic diseases, which have a significant impact on quality of life 
and mortality. The analyzed material included hospital procedures and services 
indicated by the NHF in 2011. Results: Using the Pearson’s linear Correlation test, 
dependence between variables (the average cost of hospitalization and the number 
of patients) for 23 therapeutic areas was assessed. The results showed that the lower 
prevalence (fewer patients with the diagnosis) is connected with the higher average 
unit cost of treatment. ConClusions: In Poland, among all studied diseases the 
most expensive was the individual treatment of patients diagnosed with ultrarare 
diseases (i. a. Lysosomal storage diseases). Chronic ischemic heart disease, hyper-
tension and diabetes mellitus were associated with the largest number of annual 
hospitalizations and globally were the most cost-intensive for NHF. At the same 
time hypertension is associated with the lowest average unit cost of hospitalization 
among all studied diseases.
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objeCtives: Payers all need evidence of clinical effectiveness, reasonable cost, and 
safety. Although, patient-reported outcomes (PROs) are an important component of 
this evidence it is not always clear which PROs to use and reliance on an incorrect 
PRO can have negative consequences. The objective was to describe the factors 
determining which PROs are most likely to meet payer evidence needs. Methods: 
A structured discussion of factors influencing PRO choice was held between experts 
in late phase studies, evidence review, and economic modelling. These were then 
validated against a sample of published reimbursement decisions across multiple 
disease areas. Results: Focus of most questions is on whether to use a generic, 
disease-specific or novel measure. Disease specific PROs are very frequently of value 
in demonstrating clinical effectiveness and may be the standard clinical outcome. 
For example, migraine studies include pain assessment and headache frequency. To 
facilitate Payers’ decision making generic PROs such as EQ-5D and SF-36 are com-
monly used for assessing quality of life (QoL). However these instruments may not 
be reliable in disease areas characterised by focal impacts on patient wellbeing. For 
example, pain is only a small component of the SF-36 consequently changes in pain 
levels cannot be measured with great precision and the extreme effects of pain may 
be missed when generating estimates of utility. ConClusions: When choosing a 
PRO, it is important to consider the disease, treatment and payer reimbursement 
decision context. Disease specific QoL measures may be more sensitive than a 
generic tool but may also need mapping to a general QoL measure. Acceptance will 
be contingent on the existence of robust evidence either from published literature 
or additionally collected data. Reviews of previous HTA submissions and payer deci-
sions help identify requirements / standard practices in key markets and identify 
common criticisms or problems.
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objeCtives: Greece is under a very tough and strict memorandum enforced by 
the European Union that has designed and applied austerity measures in order 
to save Greek economy and minimizes its public debt. Also the Greek Heath care 
system should be improved, upgraded or redesigned from scratch in order to be 
more flexible and more efficient. The legislative intervention made by the European 
Union and the memorandum in Greek Heath Care system and the Pharmaceutical 
market constituted legislative framework for the Greek Heath Care and the 
Pharmaceutical sector. Methods: Data on total pharmaceutical expenditures 
from 2009-2011, some of them until 2012 were obtained from Hellenic Association 
of Pharmaceutical Companies. They were analyzed using basic statistical methods 
of observing. Results: In nearly all observed parameters was recorded their low-
ering. Total pharmaceutical expenditures per capita Δ x2009-2011= -20%, x2011= 5.073 
mil € , pharmaceutical expenditure as% of health expenditure Δ x2009-2011= -6,5%, 
x2011= 24,1%, pharmaceutical expenditure as % of GDP Δ x2009-2011= -11,1%, x2011= 
2,4%, private pharmaceutical expenditure Δ x2009-2011= -13%, x2011= 1.094 mil € , pri-
vate pharmaceutical expenditure per capita Δ x2009-2011= -13,5%, x2011= 96 € , public 
pharmaceutical expenditure Δ x2009-2012= -36,8%, x2012= 3.215 € , public pharmaceu-
